Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Fineline Cube Sep 9, 2026
Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Fineline Cube Sep 9, 2026
Company Drug

Aosaikang Receives FDA Approval for ASKG915 Clinical Trial

Fineline Cube Dec 20, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its...

Company Deals

Pfizer Exercises Option for Sisunatovir Rights with LianBio

Fineline Cube Dec 20, 2022

US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise...

Company Deals

Fosun Pharma Registers Comirnaty Vaccines in Hong Kong

Fineline Cube Dec 20, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced that Comirnaty (BNT162b2) and Comirnaty bivalent...

Company Deals

XtalPi Partners with Singapore’s EDDC to Develop Lung Cancer Treatments

Fineline Cube Dec 20, 2022

Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with the Experimental Drug...

Deals

Prenetics Acquires Majority Stake in ACT Genomics to Boost Oncology Services

Fineline Cube Dec 20, 2022

Hong Kong-based Prenetics Global Ltd (NASDAQ: PRE) has announced the acquisition of a majority stake...

Company Drug

CStone’s Sugemalimab MAA Accepted by UK MHRA for NSCLC Treatment

Fineline Cube Dec 20, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the Medicines and Healthcare products Regulatory Agency...

Company Drug

Ascletis Pharma Receives USPTO Notice for ASC10 Patent

Fineline Cube Dec 20, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the Notice of Issuance from the...

Company Drug

HutchMed Initiates Rolling NDA Submission for Elunate to US FDA

Fineline Cube Dec 20, 2022

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the initiation of a rolling...

Legal / IP Policy / Regulatory

PCAOB Report Signals Relief for US-Listed Chinese Biotechs

Fineline Cube Dec 20, 2022

A report issued last week by the US Public Company Accounting Oversight Board (PCAOB) indicated...

Company Deals

Luye Pharma’s Shandong Boan Biotechnology IPOs on Hong Kong Stock Exchange

Fineline Cube Dec 19, 2022

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd has officially...

Company Drug

Simcere Pharmaceutical Completes Enrollment for SIM0417 COVID-19 Drug Trial

Fineline Cube Dec 19, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the completion of enrollment of 1,208 patients...

Company Drug

Neurophth’s NFS-02 Gene Therapy Gets FDA IND Approval for LHON Treatment

Fineline Cube Dec 19, 2022

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced obtaining Investigational New Drug (IND) approval...

Company Drug

TG ImmunoPharma Gains FDA Approval for Phase I Study of Anti-PVRIG Antibody

Fineline Cube Dec 19, 2022

China-based TG ImmunoPharma Co., Ltd has announced receiving the go-ahead from the US FDA to...

Company Deals Drug

Adagene Initiates International Study for ADG126 in Hepatocellular Carcinoma

Fineline Cube Dec 19, 2022

China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...

Company Drug

Jiangsu Recbio’s Herpes Zoster Vaccine REC610 Gets Clinical Trial Approval in Philippines

Fineline Cube Dec 19, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced receiving clinical trial...

Company Deals

Endo International Licenses TLC’s Phase III Nanomedicine for OA Knee Pain

Fineline Cube Dec 19, 2022

Ireland-based Endo International plc (NASDAQ: ENDP) has announced a licensing deal between its subsidiary Endo...

Company Drug

GenFleet and Merck KGaA Partner on European Clinical Study for KRAS G12C Inhibitor

Fineline Cube Dec 19, 2022

China-based GenFleet Therapeutics Inc. has announced a European multi-center clinical study and drug supply agreement...

Company Medical Device

Blue Sail Medical’s Microcatheter Receives NMPA Marketing Approval

Fineline Cube Dec 19, 2022

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced obtaining marketing approval from the...

Company Deals

Meihua Medtech Secures Over RMB 100M in Series B Financing Led by Eight Roads and Sunland

Fineline Cube Dec 19, 2022

China’s Zhuhai Meihua Medical Technology Co., Ltd, a leading clinical microbiology laboratory overall solutions provider,...

Company Deals

InnerMedical Secures RMB 300M in Series D Funding Led by Green Pine and Simiao

Fineline Cube Dec 19, 2022

InnerMedical Co., Ltd, a leading chronic disease diagnosis and treatment solutions provider based in Shenzhen,...

Posts pagination

1 … 637 638 639 … 718

Recent updates

  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
  • Ascletis Pharma Initiates US Phase 1 Study of ASC36 Oral Tablets – An Oral Amylin Receptor Agonist for Obesity, Advancing a Dual‑Format Program Alongside Its Once‑Monthly Injectable
  • Guangzhou Baiyunshan Pharma Wins Registration and Marketing Approval in Macau for Its Freeze‑Dried Rabies Vaccine (Vero Cells) – Joining a Highly Concentrated Supplier Landscape
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Policy / Regulatory

China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity

Company Drug

Ascletis Pharma Initiates US Phase 1 Study of ASC36 Oral Tablets – An Oral Amylin Receptor Agonist for Obesity, Advancing a Dual‑Format Program Alongside Its Once‑Monthly Injectable

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.